A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 36(3): 407-415, 2018 06.
Article
in En
| MEDLINE
| ID: mdl-28932928
Full text:
1
Database:
MEDLINE
Main subject:
Boron Compounds
/
Carbon Radioisotopes
/
Proteasome Inhibitors
/
Glycine
/
Neoplasms
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Invest New Drugs
Year:
2018
Type:
Article
Affiliation country:
United States